[Albumin Dialysis and Molecular Adsorbent Recirculating System (MARS) in the treatment of liver failure]

Atienza G
Record ID 32009100347
Spanish
Authors' objectives:

To assess the medical efficacy and safety of extracorporeal albumin dialysis using the MARS® system in the treatment of acute and acute-on-chronic liver failure (AoCLF), and to estimate the cost of this technology versus standard medical treatment.

Authors' recomendations: The MARS® system reduces mortality non-significantly, both in patients with acute and those with acute-on-chronic liver failure. Its principal indication would be in patients with severe liver failure, while the organ regenerates or is transplanted. It use should, in all cases, be limited in time, usually to sessions of six to eight hours daily. This technique can be considered safe and well-tolerated by patients, with adverse effects similar to those that appear in the control group. In addition, it brings about favourable haemodynamic changes in patients, reduces the grade of hepatic encephalopathy and that of plasma concentration of bilirubin and creatinine, though these levels tend to rise when treatment is halted. From an economic point of view, the MARS® system yielded an important saving per every surviving patient.
Authors' methods: review
Details
Project Status: Completed
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Liver Failure
  • Renal Dialysis
  • Sorption Detoxification
Contact
Organisation Name: Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
Contact Address: Conselleria de Sanidade, Xunta de Galicia, San Lazaro s/n 15781 Santiago de Compostela, Spain. Tel: 34 981 541831; Fax: 34 981 542854;
Contact Name: avalia-t@sergas.es
Contact Email: avalia-t@sergas.es
Copyright: Galician Agency for Health Technology Assessment (AVALIA-T)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.